NNC0519-0130
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Novo Nordisk · Phase 2 · Recruiting · Enrollment 465
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Dosing scheme a: NNC0519-0130 | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme a: Placebo | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme b: NNC0519-0130 | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme b: Placebo | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme c: NNC0519-0130 | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme c: Placebo | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme d: NNC0519-0130 | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme d: Placebo | Chronic Kidney Disease | n/r | 43 | n/r | n/r |
| Dosing scheme e: Semaglutide | Chronic Kidney Disease | n/r | 43 | n/r | n/r |